Screening for HCV in pregnant women and their partners

Millbourn, Charlotta; Lybeck, Charlotte; Fadl, Helena; Fredlund, Hans; Lindahl, Karin; Duberg, Ann‐Sofi

doi:10.1016/s0168-8278(17)31167-4

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the 3B-study was performed in Funen, a region where the focus on HCV testing has been high, and it is possible that this is lower in other regions. Our diagnosed proportion was similar to Sweden, where a recent hepatitis C survey found that 73% of people who tested antiHCV positive had been previously diagnosed [26]. A recent systematic review found that 13 EU/EEA countries had conducted HCV prevalence surveys with an estimated antiHCV prevalence in the EU/EEA of 1.1% (95% CI 0.9-1.4%) of which an estimated 70% have CHC [27].…”

Section: Plos Onesupporting

confidence: 80%

Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers

et al. 2020

View full text Add to dashboard Cite

Background Chronic hepatitis C (CHC) can be eliminated as a public health threat by meeting the WHO targets: 90% of patients diagnosed and 80% treated by 2030. To achieve and monitor progress towards elimination, an updated estimate of the size of the CHC population is needed, but Denmark has no complete national CHC register. By combining existing registers in 2007, we estimated the population living with CHC to be 16,888 (0.38% of the adult population). Aim To estimate the population living with diagnosed and undiagnosed CHC in Denmark on 31 December 2016. Among additional aims were to estimate the proportion of patients attending specialised clinical care. Methods People with diagnosed CHC were identified from four national registers. The total diagnosed population was estimated by capture-recapture analysis. The undiagnosed population was estimated by comparing the register data with data from two cross-sectional surveys. Results The population living with diagnosed CHC in Denmark was 7,581 persons (95%CI: 7,416-12,661) of which 6,116 (81%) were identified in the four registers. The estimated undiagnosed

show abstract

Section: Plos Onesupporting

confidence: 80%

Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The decreasing number of new diagnoses in the older population probably indicates that a large proportion has been diagnosed. A recent Swedish study of pregnant women and their partners (mean age: 30 years) demonstrated an HCV RNA prevalence of 0.4%, and only 17% were not previously diagnosed [ 17 ]. Among all estimated HCV infections in Denmark, 54% had been recorded in at least one of four national registers by 2007 and 76% by 2016, suggesting that the proportion of HCV-infected persons identified in the registers has increased in this period [ 12 , 33 , 39 , 40 ].…”

Section: Discussionmentioning

confidence: 99%

“…The second group comprises recently infected young PWID with a higher chance of diagnosis in healthcare (e.g. during treatment for drug use or in harm reduction programmes) [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C time trends in reported cases and estimates of the hidden population born before 1965, Denmark and Sweden, 1990 to 2020

et al. 2022

View full text Add to dashboard Cite

Background According to the World Health Organization, hepatitis C virus (HCV) infection should be under control by 2030. Aim Our aim was to describe the size and temporal changes in reported cases of chronic HCV infection in Denmark and Sweden and to estimate the size of the hidden (undiagnosed) population born before 1965. Methods We extracted all HCV infections reported to national surveillance systems in Denmark and Sweden from 1990 to 2020. Prediction of the size of the hidden HCV-infected population was restricted to the cohort born before 1965 and cases reported up to 2017. We applied a model based on removal sampling from binomial distributions, estimated the yearly probability of diagnosis, and deducted the original HCV-infected population size. Results Denmark (clinician-based) reported 10 times fewer hepatitis C cases annually than Sweden (laboratory and clinician-based), peaking in 2007 (n = 425) and 1992 (n = 4,537), respectively. In Denmark, the birth year distribution was monophasic with little change over time. In recent years, Sweden has had a bimodal birth year distribution, suggesting ongoing infection in the young population. In 2017, the total HCV-infected population born before 1965 was estimated at 10,737 living persons (95% confidence interval (CI): 9,744–11,806), including 5,054 undiagnosed, in Denmark and 16,124 (95% CI: 13,639–18,978), including 10,580 undiagnosed, in Sweden. Conclusions The reporting of HCV cases in Denmark and Sweden was different. For Denmark, the estimated hidden population was larger than the current national estimate, whereas in Sweden the estimate was in line with the latest published numbers.

show abstract

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update

et al. 2019

View full text Add to dashboard Cite

Background Although significant improvement in efficacy measured by a sustained virological response, the high acquisition costs of direct-acting antivirals limit the access for patients and influence the costs of healthcare resource utilisation in hepatitis C. It is important to have the latest estimates of prevalence, especially in high-risk groups, for cost of illness, cost-effectiveness and budget impact studies. Methods Original studies on the estimates of the prevalence among general and high-risk groups in the European Union/European Economic Area (EU/EEA) were retrieved from Medline and Embase for the period from 2015 to 2018. All included studies were evaluated for risk of selection bias and summarised together in a narrative form. Results from previous reviews and updated searches were compared per country among different populations, respectively. Results Among the 3871 studies identified, 46 studies were included: 20 studies were used for the estimate of the general population; 3 for men who have sex with men (MSM); 6 for prisoners; and 17 for people who inject drugs (PWID). Compared with the results reported in previous systematic reviews, the updated estimates were lower than previously in most available countries. Anti-HCV general population prevalence estimates ranged from 0.54 to 1.50% by country. The highest prevalence of anti-HCV was found among PWID (range of 7.90–82.00%), followed by prisoners (7.00–41.00%), HIV-positive MSM (1.80–7.10%), HIV-negative MSM (0.20–1.80%), pregnant women (0.10–1.32%) and first-time blood donors (0.03–0.09%). Conclusions Our study highlights the heterogeneity in anti-HCV prevalence across different population groups in EU/EEA. The prevalence also varies widely between European countries. There are many countries that are not represented in our results, highlighting the need for the development of robust epidemiological studies. Electronic supplementary material The online version of this article (10.1186/s12879-019-4284-9) contains supplementary material, which is available to authorized users.

show abstract

Screening for HCV in pregnant women and their partners

Cited by 3 publications

References 0 publications

Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers

Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers

Hepatitis C time trends in reported cases and estimates of the hidden population born before 1965, Denmark and Sweden, 1990 to 2020

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update

Contact Info

Product

Resources

About